aspartic acid has been researched along with Breast Neoplasms in 55 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study aimed to explore the potential of hydroxylated carbon nanotubes (CNTnols) conjugated with aspartic acid for the delivery of docetaxel (DTX) to breast cancer cells." | 7.91 | Aspartic acid tagged carbon nanotubols as a tool to deliver docetaxel to breast cancer cells: Reduced hemotoxicity with improved cytotoxicity. ( Babu, PV; Chitkara, D; Khurana, RK; Kumar, V; Raza, K; Sharma, S; Singh, B; Thotakura, N, 2019) |
| " Here, we synthesized a pH-sensitive polymer, poly(ethylene glycol)-benzoic imine-poly(γ-benzyl-l-aspartate)-b-poly(1-vinylimidazole) block copolymer (PPBV), to develop a pH multistage responsive micellar system for co-delivering paclitaxel and curcumin and synergistically eliminating breast cancer stem cells (bCSCs) and non-bCSCs." | 7.85 | pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. ( Cheng, R; Li, X; Liu, J; Liu, Z; Sun, N; Tian, Z; Yang, Z; Zhao, C, 2017) |
| "The mouse models of human breast cancer also indicated significant target enhancements of cRGD-Gd-DTPA-PLGA magnetic nanoparticles in the mouse tumor." | 5.72 | Ultrasound and magnetic resonance imaging of cyclic arginine glycine aspartic acid-gadopentetic acid-polylactic acid in human breast cancer by targeting αvβ3 in xenograft-bearing nude mice. ( Chen, M; Fu, D; Huang, X; Lv, Z; Su, D; Zhang, W; Zhang, Y, 2022) |
| "It was concluded that in brain metastases of mammary carcinoma Lact represents a product of ischemia preceding/during tissue decay resulting in central necrosis, rather than tumor specific metabolism resulting in increased glycolysis." | 5.29 | Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. ( Oudkerk, M; Sijens, PE; van Dijk, P, 1994) |
| " Here, we show that ASS1 functions as a tumor suppressor in breast cancer, and the pesticide spinosyn A (SPA) and its derivative LM-2I suppress breast tumor cell proliferation and growth by binding to and activating ASS1." | 4.02 | Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor. ( Cao, D; Chen, C; Chen, L; Chen, X; Hu, X; Kong, F; Li, J; Li, X; Liu, O; Liu, S; Luo, J; Luo, T; Luo, W; Luo, Z; Ma, D; Ming, Z; Peng, K; Wen, M; Xia, L; Xie, Y; Xu, N; Yang, C; Yi, W; Zou, Z, 2021) |
| "The present study aimed to explore the potential of hydroxylated carbon nanotubes (CNTnols) conjugated with aspartic acid for the delivery of docetaxel (DTX) to breast cancer cells." | 3.91 | Aspartic acid tagged carbon nanotubols as a tool to deliver docetaxel to breast cancer cells: Reduced hemotoxicity with improved cytotoxicity. ( Babu, PV; Chitkara, D; Khurana, RK; Kumar, V; Raza, K; Sharma, S; Singh, B; Thotakura, N, 2019) |
| " Here, we synthesized a pH-sensitive polymer, poly(ethylene glycol)-benzoic imine-poly(γ-benzyl-l-aspartate)-b-poly(1-vinylimidazole) block copolymer (PPBV), to develop a pH multistage responsive micellar system for co-delivering paclitaxel and curcumin and synergistically eliminating breast cancer stem cells (bCSCs) and non-bCSCs." | 3.85 | pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells. ( Cheng, R; Li, X; Liu, J; Liu, Z; Sun, N; Tian, Z; Yang, Z; Zhao, C, 2017) |
| " In our experiments, human breast cancer cells primarily assimilated ammonia through reductive amination catalyzed by glutamate dehydrogenase (GDH); secondary reactions enabled other amino acids, such as proline and aspartate, to directly acquire this nitrogen." | 3.85 | Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. ( Clish, CB; Haigis, MC; Jeanfavre, S; Ringel, AE; Spinelli, JB; Yoon, H, 2017) |
| "Eight patients with advanced breast cancer were entered into a prospective, longitudinal trial that included examination by MR imaging and proton MR spectroscopy before chemotherapy and through 12 months after treatment with carmustine, cyclophosphamide, and cisplatin, combined with autologous hematopoietic progenitor cell support (AHPCS)." | 3.70 | White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. ( Brown, MS; Cagnoni, PJ; Jones, RB; Sheeder, JL; Simon, JH; Stears, JC; Stemmer, SM, 1998) |
| "Cultured wild-type MCF-7 human breast cancer cells and two MCF-7 sublines that overproduce enzymes of the de novo pyrimidine biosynthetic pathway were compared with regard to: rate of de novo biosynthesis of uracil nucleotides, sensitivity of the de novo and salvage pathways to the concentration of intracellular uracil nucleotides, and potential of exogenous uridine at concentrations equivalent to plasma levels to affect de novo pyrimidine biosynthesis." | 3.67 | Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway. ( Chisena, CA; Cowan, KH; Cysyk, RL; Karle, JM, 1986) |
| "Four of ten patients with colorectal cancer responded to the treatment (four partial responses), of whom three had been treated previously." | 2.67 | A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. ( Ardalan, B; Benedetto, P; Feun, L; Fodor, M; Livingstone, A; Morrell, L; Richman, S; Savaraj, N; Sridhar, KS; Waldman, S, 1991) |
| "Sixty-three patients with Stage IV breast carcinoma refractory to standard combination chemotherapy agents such as 5-fluorouracil (5-FU) were entered into a study to determine the efficacy of a multiple dose schedule of N-(phosphonacetyl)-L-aspartic acid (PALA) and whether the addition of PALA improves the therapeutic efficacy of 5-FU." | 2.66 | A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. ( Buzdar, AU; Hortobagyi, GN; Mann, GB; Valdivieso, M; Yap, HY, 1985) |
| "Aspartic acid is considered to be an important substrate for nucleotide synthesis." | 1.91 | FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer. ( Chen, C; Li, Z; Liu, T; Ye, L; Yi, J, 2023) |
| "The mouse models of human breast cancer also indicated significant target enhancements of cRGD-Gd-DTPA-PLGA magnetic nanoparticles in the mouse tumor." | 1.72 | Ultrasound and magnetic resonance imaging of cyclic arginine glycine aspartic acid-gadopentetic acid-polylactic acid in human breast cancer by targeting αvβ3 in xenograft-bearing nude mice. ( Chen, M; Fu, D; Huang, X; Lv, Z; Su, D; Zhang, W; Zhang, Y, 2022) |
| "Respectively, prostate cancer (PCa) and breast cancer (BC) are the second most and most commonly diagnosed cancer in men and women, and they account for a majority of cancer-related deaths world-wide." | 1.72 | Effects of glutamate and aspartate on prostate cancer and breast cancer: a Mendelian randomization study. ( Li, J; Lin, Y; Luo, Y; Qu, Z; Sun, Y; Yang, Z; Zhang, L; Zhang, X, 2022) |
| "Samples of 13 patients with metastatic breast cancer were analyzed for mutations in cancer-related genes." | 1.39 | D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer. ( Ben-Baruch, N; Brown, M; Dvir, A; Jeselsohn, R; Klein, B; Merenbakh-Lamin, K; Miller, VA; Rizel, S; Rubinek, T; Sarid, D; Soussan-Gutman, L; Wolf, I; Yeheskel, A; Yelensky, R, 2013) |
| "Our results suggest that the breast cancer-associated mutations interfere with the intracellular trafficking of ADAM12 and result in loss of the functional ADAM12 at the cell surface." | 1.35 | Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. ( Dyczynska, E; Sun, D; Syta, E; Zolkiewska, A, 2008) |
| "Liver metastases from breast cancer are associated with a poor prognosis, however, local control with microwave thermocoagulation therapy has been used in certain subgroups of these patients in the past decade." | 1.33 | Open-configuration MR-guided microwave thermocoagulation therapy for metastatic liver tumors from breast cancer. ( Abe, H; Endo, Y; Hanasawa, K; Kurumi, Y; Morikawa, S; Naitoh, H; Naka, S; Shiomi, H; Tani, T; Umeda, T, 2005) |
| "A recent work comprising 269 breast cancer patients and 244 controls suggested that NOS3 Glu298Asp polymorphism is associated to breast cancer risk (OR=1." | 1.33 | Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study. ( Galán, JJ; González-Mancha, R; González-Martín, A; Moreno-Nogueira, JA; Real, LM; Royo, JL; Ruiz, A, 2006) |
| "The combined adjusted odds ratios for breast cancer were 0." | 1.32 | Association of a common variant of the CASP8 gene with reduced risk of breast cancer. ( Balasubramanian, SP; Bhattacharyya, NP; Cox, A; Healey, CS; MacPherson, G; Meuth, M; Pharoah, PD; Ponder, BA; Reed, MW; Teare, MD, 2004) |
| "Recently, four cancer-associated mutants of the A-alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64-->Gly in breast carcinoma, Arg418-->Trp in melanoma, and Delta171 - 589 in breast carcinoma." | 1.31 | Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. ( Pham, HT; Ruediger, R; Walter, G, 2001) |
| "It was concluded that in brain metastases of mammary carcinoma Lact represents a product of ischemia preceding/during tissue decay resulting in central necrosis, rather than tumor specific metabolism resulting in increased glycolysis." | 1.29 | Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma. ( Oudkerk, M; Sijens, PE; van Dijk, P, 1994) |
| "One of the responding patients with colon cancer and two with breast cancer had failed to respond to prior therapy with 5-FU; one of the responding patients with breast cancer had previously received an inadequate trial of a similar regimen." | 1.26 | Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. ( Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR, 1982) |
| "Thirty-three patients with advanced breast cancer were treated with PALA at a schedule of 1500 mg/m2/day for 5 days every 3 weeks." | 1.26 | PALA in advanced breast cancer. A phase II pilot study by the ECOG. ( Davis, TE; Falkson, G; Keller, AM; Taylor, SG, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (21.82) | 18.7374 |
| 1990's | 11 (20.00) | 18.2507 |
| 2000's | 9 (16.36) | 29.6817 |
| 2010's | 16 (29.09) | 24.3611 |
| 2020's | 7 (12.73) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, D | 1 |
| Huang, X | 1 |
| Lv, Z | 1 |
| Zhang, Y | 1 |
| Chen, M | 1 |
| Zhang, W | 2 |
| Su, D | 1 |
| Lin, Y | 1 |
| Yang, Z | 2 |
| Li, J | 3 |
| Sun, Y | 1 |
| Zhang, X | 1 |
| Qu, Z | 1 |
| Luo, Y | 1 |
| Zhang, L | 1 |
| Barboro, P | 1 |
| Rubagotti, A | 1 |
| Poddine, S | 1 |
| Grillo, F | 1 |
| Mastracci, L | 1 |
| Boccardo, F | 1 |
| Bhattacharya, N | 3 |
| Kolvekar, N | 3 |
| Mondal, S | 3 |
| Sarkar, A | 3 |
| Chakrabarty, D | 3 |
| Chen, C | 2 |
| Ye, L | 1 |
| Yi, J | 1 |
| Liu, T | 1 |
| Li, Z | 1 |
| Beyer, J | 1 |
| Couch, R | 1 |
| Ruddy, KJ | 1 |
| Zeydan, B | 1 |
| Tosakulwong, N | 1 |
| Lesnick, TG | 1 |
| Novotny, PJ | 1 |
| Kohli, S | 1 |
| Cerhan, JH | 1 |
| Pruthi, S | 1 |
| Kantarci, K | 1 |
| Kara, F | 1 |
| Zou, Z | 1 |
| Hu, X | 1 |
| Luo, T | 1 |
| Ming, Z | 1 |
| Chen, X | 1 |
| Xia, L | 1 |
| Luo, W | 1 |
| Xu, N | 1 |
| Chen, L | 1 |
| Cao, D | 1 |
| Wen, M | 1 |
| Kong, F | 1 |
| Peng, K | 1 |
| Xie, Y | 1 |
| Li, X | 2 |
| Ma, D | 1 |
| Yang, C | 1 |
| Yi, W | 1 |
| Liu, O | 1 |
| Liu, S | 1 |
| Luo, J | 1 |
| Luo, Z | 1 |
| Sun, N | 1 |
| Cheng, R | 1 |
| Zhao, C | 1 |
| Liu, Z | 1 |
| Liu, J | 1 |
| Tian, Z | 1 |
| Spinelli, JB | 1 |
| Yoon, H | 1 |
| Ringel, AE | 1 |
| Jeanfavre, S | 1 |
| Clish, CB | 1 |
| Haigis, MC | 1 |
| Chen, BB | 1 |
| Lu, YS | 1 |
| Yu, CW | 1 |
| Lin, CH | 1 |
| Chen, TW | 1 |
| Wei, SY | 1 |
| Cheng, AL | 1 |
| Shih, TT | 1 |
| Bertero, T | 1 |
| Oldham, WM | 1 |
| Grasset, EM | 1 |
| Bourget, I | 1 |
| Boulter, E | 1 |
| Pisano, S | 1 |
| Hofman, P | 1 |
| Bellvert, F | 1 |
| Meneguzzi, G | 1 |
| Bulavin, DV | 1 |
| Estrach, S | 1 |
| Feral, CC | 1 |
| Chan, SY | 1 |
| Bozec, A | 1 |
| Gaggioli, C | 1 |
| Hong, R | 1 |
| Xia, X | 1 |
| Zhang, K | 1 |
| Wang, Y | 1 |
| Wu, M | 1 |
| Fan, J | 1 |
| Xia, W | 1 |
| Xu, F | 1 |
| Chen, J | 1 |
| Wang, S | 1 |
| Zhan, Q | 1 |
| Thotakura, N | 1 |
| Sharma, S | 1 |
| Khurana, RK | 1 |
| Babu, PV | 1 |
| Chitkara, D | 1 |
| Kumar, V | 1 |
| Singh, B | 1 |
| Raza, K | 1 |
| Bacci, M | 1 |
| Lorito, N | 1 |
| Ippolito, L | 1 |
| Ramazzotti, M | 1 |
| Luti, S | 1 |
| Romagnoli, S | 1 |
| Parri, M | 1 |
| Bianchini, F | 1 |
| Cappellesso, F | 1 |
| Virga, F | 1 |
| Gao, Q | 1 |
| Simões, BM | 1 |
| Marangoni, E | 1 |
| Martin, LA | 1 |
| Comito, G | 1 |
| Ferracin, M | 1 |
| Giannoni, E | 1 |
| Mazzone, M | 1 |
| Chiarugi, P | 1 |
| Morandi, A | 1 |
| Merenbakh-Lamin, K | 1 |
| Ben-Baruch, N | 1 |
| Yeheskel, A | 1 |
| Dvir, A | 1 |
| Soussan-Gutman, L | 1 |
| Jeselsohn, R | 1 |
| Yelensky, R | 1 |
| Brown, M | 1 |
| Miller, VA | 1 |
| Sarid, D | 1 |
| Rizel, S | 1 |
| Klein, B | 1 |
| Rubinek, T | 1 |
| Wolf, I | 1 |
| Zick, SM | 1 |
| Zwickey, H | 1 |
| Wood, L | 1 |
| Foerster, B | 1 |
| Khabir, T | 1 |
| Wright, B | 1 |
| Ichesco, E | 1 |
| Sen, A | 1 |
| Harris, RE | 1 |
| Endo, Y | 2 |
| Dong, Y | 1 |
| Yoshimoto, N | 1 |
| Asano, T | 1 |
| Hato, Y | 1 |
| Yamashita, H | 1 |
| Sato, S | 1 |
| Takahashi, S | 1 |
| Fujii, Y | 1 |
| Toyama, T | 1 |
| Jordan, VC | 2 |
| Curpan, R | 1 |
| Maximov, PY | 1 |
| Xie, G | 1 |
| Zhou, B | 1 |
| Zhao, A | 1 |
| Qiu, Y | 1 |
| Zhao, X | 1 |
| Garmire, L | 1 |
| Shvetsov, YB | 1 |
| Yu, H | 1 |
| Yen, Y | 1 |
| Jia, W | 1 |
| Mohsen, A | 1 |
| Saby, C | 1 |
| Collery, P | 1 |
| Sabry, GM | 1 |
| Hassan, RE | 1 |
| Badawi, A | 1 |
| Jeannesson, P | 1 |
| Desmaële, D | 1 |
| Morjani, H | 1 |
| Phannasil, P | 1 |
| Ansari, IH | 1 |
| El Azzouny, M | 1 |
| Longacre, MJ | 1 |
| Rattanapornsompong, K | 1 |
| Burant, CF | 1 |
| MacDonald, MJ | 1 |
| Jitrapakdee, S | 1 |
| Ruttala, HB | 1 |
| Ramasamy, T | 1 |
| Shin, BS | 1 |
| Choi, HG | 1 |
| Yong, CS | 1 |
| Kim, JO | 1 |
| Donini, CF | 1 |
| Di Zazzo, E | 1 |
| Zuchegna, C | 1 |
| Di Domenico, M | 1 |
| D'Inzeo, S | 1 |
| Nicolussi, A | 1 |
| Avvedimento, EV | 1 |
| Coppa, A | 1 |
| Porcellini, A | 1 |
| Ying, H | 1 |
| Subrata, S | 1 |
| RYAN, WL | 1 |
| LORINCZ, AB | 1 |
| MacPherson, G | 1 |
| Healey, CS | 1 |
| Teare, MD | 1 |
| Balasubramanian, SP | 1 |
| Reed, MW | 1 |
| Pharoah, PD | 1 |
| Ponder, BA | 1 |
| Meuth, M | 1 |
| Bhattacharyya, NP | 1 |
| Cox, A | 1 |
| Abe, H | 1 |
| Kurumi, Y | 1 |
| Naka, S | 1 |
| Shiomi, H | 1 |
| Umeda, T | 1 |
| Naitoh, H | 1 |
| Hanasawa, K | 1 |
| Morikawa, S | 1 |
| Tani, T | 1 |
| Frank, B | 1 |
| Bermejo, JL | 1 |
| Hemminki, K | 1 |
| Klaes, R | 1 |
| Bugert, P | 1 |
| Wappenschmidt, B | 1 |
| Schmutzler, RK | 1 |
| Burwinkel, B | 1 |
| Fowler, AM | 1 |
| Solodin, NM | 1 |
| Valley, CC | 1 |
| Alarid, ET | 1 |
| Esplin, ED | 1 |
| Ramos, P | 1 |
| Martinez, B | 1 |
| Tomlinson, GE | 1 |
| Mumby, MC | 1 |
| Evans, GA | 1 |
| Royo, JL | 1 |
| Moreno-Nogueira, JA | 1 |
| Galán, JJ | 1 |
| González-Martín, A | 1 |
| Ruiz, A | 1 |
| González-Mancha, R | 1 |
| Real, LM | 1 |
| Dyczynska, E | 1 |
| Syta, E | 1 |
| Sun, D | 1 |
| Zolkiewska, A | 1 |
| Paridaens, R | 1 |
| Mouridsen, HT | 1 |
| Palshof, T | 1 |
| Cocconi, G | 1 |
| Van Oosterom, A | 1 |
| Rotmensz, N | 1 |
| Sylvester, R | 1 |
| Heuson, JC | 1 |
| Rozencweig, M | 1 |
| Ardalan, B | 3 |
| Jamin, D | 1 |
| Jayaram, HN | 2 |
| Presant, CA | 1 |
| Weiss, GR | 1 |
| Ervin, TJ | 1 |
| Meshad, MW | 1 |
| Kufe, DW | 1 |
| Taylor, SG | 1 |
| Davis, TE | 1 |
| Falkson, G | 1 |
| Keller, AM | 1 |
| Glazer, RI | 1 |
| Kensler, TW | 1 |
| Van Pham, T | 1 |
| Macdonald, JS | 1 |
| Cooney, DA | 2 |
| Sijens, PE | 1 |
| van Dijk, P | 1 |
| Oudkerk, M | 1 |
| Cleaveland, ES | 1 |
| Zaharevitz, DW | 1 |
| Kelley, JA | 1 |
| Paull, K | 1 |
| Ford, H | 1 |
| Gudas, JM | 1 |
| Nguyen, H | 1 |
| Li, T | 1 |
| Sadzewicz, L | 1 |
| Robey, R | 1 |
| Wosikowski, K | 1 |
| Cowan, KH | 2 |
| Brown, MS | 1 |
| Stemmer, SM | 1 |
| Simon, JH | 1 |
| Stears, JC | 1 |
| Jones, RB | 1 |
| Cagnoni, PJ | 1 |
| Sheeder, JL | 1 |
| Levenson, AS | 1 |
| Paranavitana, CM | 1 |
| Martínez, JM | 1 |
| Prieto, I | 1 |
| Ramírez, MJ | 1 |
| Cueva, C | 1 |
| Alba, F | 1 |
| Ramírez, M | 1 |
| Ruediger, R | 1 |
| Pham, HT | 1 |
| Walter, G | 1 |
| Mizumura, Y | 1 |
| Matsumura, Y | 1 |
| Hamaguchi, T | 1 |
| Nishiyama, N | 1 |
| Kataoka, K | 1 |
| Kawaguchi, T | 1 |
| Hrushesky, WJ | 1 |
| Moriyasu, F | 1 |
| Kakizoe, T | 1 |
| Santos, O | 1 |
| Pant, KD | 1 |
| Blank, EW | 1 |
| Ceriani, RL | 1 |
| Sridhar, KS | 1 |
| Benedetto, P | 1 |
| Richman, S | 1 |
| Waldman, S | 1 |
| Morrell, L | 1 |
| Feun, L | 1 |
| Savaraj, N | 1 |
| Fodor, M | 1 |
| Livingstone, A | 1 |
| Allegra, CJ | 1 |
| Karle, JM | 1 |
| Chisena, CA | 1 |
| Cysyk, RL | 1 |
| Mann, GB | 1 |
| Hortobagyi, GN | 1 |
| Buzdar, AU | 1 |
| Yap, HY | 1 |
| Valdivieso, M | 1 |
| Briscoe, WT | 1 |
| Taylor, W | 1 |
| Griffin, AC | 1 |
| Duff, R | 1 |
| Rapp, F | 1 |
| Kronberger, L | 2 |
| Fink, E | 2 |
| Daill, M | 1 |
| Schindler, R | 1 |
| Nieper, A | 1 |
2 trials available for aspartic acid and Breast Neoplasms
| Article | Year |
|---|---|
A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; B | 1991 |
A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Breast Neoplasms; Female | 1985 |
53 other studies available for aspartic acid and Breast Neoplasms
| Article | Year |
|---|---|
Ultrasound and magnetic resonance imaging of cyclic arginine glycine aspartic acid-gadopentetic acid-polylactic acid in human breast cancer by targeting αvβ3 in xenograft-bearing nude mice.
Topics: Animals; Arginine; Aspartic Acid; Breast Neoplasms; Contrast Media; Female; Gadolinium DTPA; Glycine | 2022 |
Effects of glutamate and aspartate on prostate cancer and breast cancer: a Mendelian randomization study.
Topics: Adult; Aspartic Acid; Breast Neoplasms; Glutamic Acid; Humans; Male; Mendelian Randomization Analysi | 2022 |
The prognostic value of aspartate beta-hydroxylase in early breast cancer.
Topics: Aspartic Acid; Breast Neoplasms; Calcium-Binding Proteins; Cohort Studies; Female; Humans; Mixed Fun | 2022 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
SPAD-1, a serine proteinase associated disintegrin from Russell's viper venom disrupts adhesion of MCF7 human breast cancer cells.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Daboia; Disintegrins; Female; Fibronectins; Histidine; Hum | 2023 |
FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.
Topics: Apoptosis; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2023 |
Longitudinal cognitive function and brain metabolites in women receiving chemotherapy for stage 1 to 3 breast cancer: Observational study.
Topics: Aspartic Acid; Brain; Breast Neoplasms; Choline; Cognition; Creatine; Female; Gyrus Cinguli; Humans | 2023 |
Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor.
Topics: Adult; Aged; Animals; Argininosuccinate Synthase; Aspartic Acid; Breast; Breast Neoplasms; Cell Line | 2021 |
pH multistage responsive micellar system with charge-switch and PEG layer detachment for co-delivery of paclitaxel and curcumin to synergistically eliminate breast cancer stem cells.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cu | 2017 |
Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass.
Topics: Amination; Ammonia; Animals; Aspartic Acid; Biocatalysis; Breast Neoplasms; Cell Proliferation; Fema | 2017 |
Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; Breast Neopla | 2018 |
Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aspartic Acid; Breast Neoplasms; Cancer-Associated Fi | 2019 |
Preventing BRCA1/ZBRK1 repressor complex binding to the GOT2 promoter results in accelerated aspartate biosynthesis and promotion of cell proliferation.
Topics: Animals; Aspartate Aminotransferase, Mitochondrial; Aspartic Acid; Biomarkers, Tumor; BRCA1 Protein; | 2019 |
Aspartic acid tagged carbon nanotubols as a tool to deliver docetaxel to breast cancer cells: Reduced hemotoxicity with improved cytotoxicity.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Do | 2019 |
Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer.
Topics: Amino Acid Transport Systems; Amino Acid Transport Systems, Neutral; Animals; Aspartic Acid; Breast | 2019 |
D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents, Hormonal; Aspartic Acid; Breast Neoplasms; Carcinoma | 2013 |
Preliminary differences in peripheral immune markers and brain metabolites between fatigued and non-fatigued breast cancer survivors: a pilot study.
Topics: Aspartic Acid; Biomarkers; Brain; Breast Neoplasms; Creatine; Cross-Sectional Studies; Fatigue; Fema | 2014 |
HER2 mutation status in Japanese HER2-negative breast cancer patients.
Topics: Adult; Antineoplastic Agents; Asian People; Aspartic Acid; Biomarkers, Tumor; Breast Neoplasms; Carc | 2014 |
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
Topics: Aspartic Acid; Breast Neoplasms; Female; Heterografts; Humans; Mutation; Receptors, Estrogen; Select | 2015 |
Lowered circulating aspartate is a metabolic feature of human breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspartic Acid; Biomarkers, Tumor; Breast Neoplasms; Case | 2015 |
Biological study of the effect of water soluble [N-(2-hydroxybenzyl)-L-aspartato] gallium complexes on breast carcinoma and fibrosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Breast Neoplasms; Caspase 3; Caspase 7; Cell Cycle | 2016 |
Mass spectrometry analysis shows the biosynthetic pathways supported by pyruvate carboxylase in highly invasive breast cancer cells.
Topics: Acetyl Coenzyme A; Aspartic Acid; Biosynthetic Pathways; Breast Neoplasms; Cell Line, Tumor; Cell Pr | 2017 |
Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Animals; Aspartic Acid; Breast Neoplasms; Cell Line, Tumor; Female; Humans | 2017 |
The p85α regulatory subunit of PI3K mediates cAMP-PKA and retinoic acid biological effects on MCF7 cell growth and migration.
Topics: Alanine; Animals; Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cattle; Cell Cycle Checkpo | 2012 |
[S-phase arrest associated apoptosis leads to diversities of drug resistance and mutation rate in human breast cancer cells].
Topics: Antineoplastic Agents; Apoptosis; Aspartic Acid; Breast Neoplasms; Drug Resistance, Neoplasm; Humans | 1999 |
FREE AMINO ACIDS OF HUMAN BREAST CANCER.
Topics: Amino Acids; Asparagine; Aspartic Acid; Breast Neoplasms; Chromatography; Citrulline; Glutamates; Gl | 1964 |
Association of a common variant of the CASP8 gene with reduced risk of breast cancer.
Topics: Aspartic Acid; Breast Neoplasms; Case-Control Studies; Caspase 10; Caspase 8; Caspases; England; Fem | 2004 |
Open-configuration MR-guided microwave thermocoagulation therapy for metastatic liver tumors from breast cancer.
Topics: Adult; Aged; Alanine Transaminase; Aspartic Acid; Breast Neoplasms; Electrocoagulation; Female; Huma | 2005 |
Re: Association of a common variant of the CASP8 gene with reduced risk of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspartic Acid; Breast Neoplasms; Case-Control Studies; Caspase 8; Ca | 2005 |
Altered target gene regulation controlled by estrogen receptor-alpha concentration.
Topics: Amino Acid Sequence; Amino Acid Substitution; Aspartic Acid; Breast Neoplasms; Complement C3; Down-R | 2006 |
The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function.
Topics: Amino Acid Substitution; Aspartic Acid; Base Sequence; Breast Neoplasms; DNA Primers; Female; Geneti | 2006 |
Lack of association between NOS3 Glu298Asp and breast cancer risk: a case-control study.
Topics: Aspartic Acid; Breast Neoplasms; Case-Control Studies; Female; Gene Expression Regulation, Neoplasti | 2006 |
Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein.
Topics: ADAM Proteins; ADAM12 Protein; Animals; Aspartic Acid; Biotinylation; Blotting, Western; Breast Neop | 2008 |
N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Breast Neoplasms; Digestive System; Dru | 1982 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU.
Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Th | 1982 |
PALA in advanced breast cancer. A phase II pilot study by the ECOG.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Bone Marrow; Breast Neoplasms; Digestive System; | 1982 |
Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Topics: Antineoplastic Agents; Aspartic Acid; Breast Neoplasms; Cell Division; Cell Line; Drug Synergism; Fe | 1981 |
Correlation between choline level and Gd-DTPA enhancement in patients with brain metastases of mammary carcinoma.
Topics: Adult; Aspartic Acid; Brain Neoplasms; Breast Neoplasms; Carcinoma; Choline; Contrast Media; Creatin | 1994 |
Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Topics: Antineoplastic Agents; Aspartic Acid; Biphenyl Compounds; Breast Neoplasms; Carbolines; Carcinoma, N | 1996 |
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone | 1996 |
White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain; Brain Diseases; B | 1998 |
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
Topics: Aspartic Acid; Blotting, Northern; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Humans | 1998 |
Non-radioactive detection of K-ras mutations by nested allele specific PCR and oligonucleotide hybridization.
Topics: Alanine; Amino Acid Substitution; Animals; Aspartic Acid; Breast Neoplasms; Codon; Colonic Neoplasms | 1998 |
Aminopeptidase activities in breast cancer tissue.
Topics: Aminopeptidases; Aspartic Acid; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Membrane; Female; | 1999 |
Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene.
Topics: Amino Acid Sequence; Arginine; Aspartic Acid; Breast Neoplasms; Female; Glutamic Acid; Glycine; Huma | 2001 |
Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Cell Survival; Cisplatin; Colonic Neoplasms; Drug Carriers | 2001 |
5-Iododeoxyuridine increases the efficacy of the radioimmunotherapy of human tumors growing in nude mice.
Topics: Animals; Aspartic Acid; Breast Neoplasms; Deoxycytidine; Drug Therapy, Combination; Humans; Idoxurid | 1992 |
Biochemical modulation: a modality that has come of therapeutic age.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brea | 1991 |
Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Topics: Amides; Aspartate Carbamoyltransferase; Aspartic Acid; Breast Neoplasms; Carbamoyl-Phosphate Synthas | 1986 |
Aspartyl transfer RNA profiles in normal and cancer cells.
Topics: Animals; Ascites; Aspartic Acid; Breast Neoplasms; Carbon Isotopes; Carcinoma, Hepatocellular; Cell | 1972 |
[Urinary excretion of asparagne and aspartate in control subjects and patients with cancer before and after treatment with K-Mg-aspartate].
Topics: Adolescent; Adult; Aged; Asparagine; Aspartic Acid; Breast Neoplasms; Cholecystitis; Female; Humans; | 1972 |
[Potassium-magnesium-aspartate therapy in operated cancer patients].
Topics: Adult; Aged; Anemia, Hypochromic; Aspartic Acid; Body Weight; Breast Neoplasms; Female; Hemoglobinom | 1971 |
Recalcification of bone metastases by calcium diorotate.
Topics: Adult; Aspartic Acid; Biological Transport, Active; Bone and Bones; Bone Neoplasms; Breast Neoplasms | 1970 |